Too Little Evidence to Recommend Cannabis for Depression, Anxiety, or PTSD
A systematic review found only 8 very small randomized controlled trials testing cannabinoids for mood disorders, anxiety, or PTSD, and concluded there is insufficient evidence to recommend medical cannabis for any of these conditions.
Quick Facts
What This Study Found
Of 8 identified RCTs, CBD pretreatment showed promise for social anxiety in laboratory settings, but THC showed no benefit for depression and actually worsened anxiety and psychotic symptoms in over 50% of hospitalized depression patients. One small crossover trial found THC reduced PTSD nightmares.
Key Numbers
8 RCTs identified; CBD: 3 studies showed anxiety reduction in social anxiety; THC up to 3 mg/day reduced anxiety in 1 trial but symptoms were already low; THC worsened anxiety/psychotic symptoms in >50% of depression patients; 1 crossover trial of 10 PTSD patients found THC reduced nightmares.
How They Did This
Systematic review searching 8 online databases for randomized controlled trials of defined CBD or THC doses in populations with affective disorders, anxiety disorders, or PTSD.
Why This Research Matters
Despite widespread use of cannabis for mental health symptoms, this review reveals that the controlled evidence base is remarkably thin, with only 8 small trials across three major diagnostic categories.
The Bigger Picture
The mismatch between the large number of people using cannabis for mental health and the tiny number of controlled trials creates a significant evidence gap that leaves both patients and clinicians without reliable guidance.
What This Study Doesn't Tell Us
Only 8 very small trials identified; heterogeneous designs, doses, and populations; insufficient evidence to draw definitive conclusions about either efficacy or harm.
Questions This Raises
- ?Why are there so few controlled trials of cannabinoids for common psychiatric conditions?
- ?Would larger, well-designed RCTs reveal benefits that small studies miss?
Trust & Context
- Key Stat:
- Only 8 randomized controlled trials exist for cannabinoids in mood disorders, anxiety, or PTSD
- Evidence Grade:
- Systematic review revealing a near-total absence of controlled evidence, limiting conclusions despite moderate review quality.
- Study Age:
- Review published in 2021.
- Original Title:
- Evidence for Use of Cannabinoids in Mood Disorders, Anxiety Disorders, and PTSD: A Systematic Review.
- Published In:
- Psychiatric services (Washington, D.C.), 72(4), 429-436 (2021)
- Authors:
- Stanciu, Corneliu N(2), Brunette, Mary F(7), Teja, Nikhil, Budney, Alan J
- Database ID:
- RTHC-03548
Evidence Hierarchy
Analyzes all available research on a topic using a structured method.
What do these levels mean? →Frequently Asked Questions
Should I use cannabis for anxiety or depression?
This systematic review found insufficient controlled evidence to recommend cannabinoids for anxiety, depression, or PTSD. While CBD showed some promise for social anxiety in lab settings, THC actually worsened symptoms in depression patients in the available studies.
Does cannabis help with PTSD?
Only one very small crossover trial (10 patients) found that THC reduced self-reported nightmares when added to standard PTSD treatment. This is insufficient evidence to draw conclusions.
Read More on RethinkTHC
Cite This Study
https://rethinkthc.com/research/RTHC-03548APA
Stanciu, Corneliu N; Brunette, Mary F; Teja, Nikhil; Budney, Alan J. (2021). Evidence for Use of Cannabinoids in Mood Disorders, Anxiety Disorders, and PTSD: A Systematic Review.. Psychiatric services (Washington, D.C.), 72(4), 429-436. https://doi.org/10.1176/appi.ps.202000189
MLA
Stanciu, Corneliu N, et al. "Evidence for Use of Cannabinoids in Mood Disorders, Anxiety Disorders, and PTSD: A Systematic Review.." Psychiatric services (Washington, 2021. https://doi.org/10.1176/appi.ps.202000189
RethinkTHC
RethinkTHC Research Database. "Evidence for Use of Cannabinoids in Mood Disorders, Anxiety ..." RTHC-03548. Retrieved from https://rethinkthc.com/research/stanciu-2021-evidence-for-use-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.